Drugs / GD2-CART01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05298995 | Nov 2023 → Nov 2027 expected | childhood medulloblastoma, diffuse intrinsic pontine glioma | Bambino Gesù Hospital and Research Institute | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03373097 | Jan 2018 → Dec 2026 expected | Ewing sarcoma, neuroblastoma, osteosarcoma | Bambino Gesù Hospital and Research Institute | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GD2-CART01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05298995 ↗ |
| Action | Deplete | “our CAR T-cells are able to induce marked tumor reduction and even achieve complete remission” PMID 34772439 ↗ Nov 2021 |
| Modality | Cell therapy | “autologous, third-generation GD2-CAR T cells expressing the inducible caspase 9 suicide gene” PMID 37018492 ↗ Apr 2023 |
| Route | Intravenous | “infused i.v. as a single dose” NCT05298995 ↗ |